Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Wisconsin Research Network |
---|---|
Information provided by: | Wisconsin Research Network |
ClinicalTrials.gov Identifier: | NCT00245908 |
The ASTHMA Pilot Study is a randomized, controlled, parallel group clinical trial of 6 weekly doses of azithromycin (cumulative dose 4800 mg) or placebo as adjunctive treatment in addition to usual care for adults with stable persistent asthma, with final follow up at 3 months after completion of study medication.
The hypothesis to be tested is that antibiotic treatment will improve asthma at followup, and that this improvement will be limited to patients with evidence of C. pneumoniae infection.
The secondary hypothesis is that randomized, controlled treatment trials can be carried out successfully in a geographically dispersed practice-based research network.
Condition | Intervention | Phase |
---|---|---|
Asthma |
Drug: azithromycin |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study |
Estimated Enrollment: | 100 |
Study Start Date: | September 1999 |
Estimated Study Completion Date: | September 2002 |
Asthma is a chronic inflammatory bronchial condition of unknown etiology. Decades ago many clinicians believed that infection played a major role in asthma etiology, but current expert opinion favors the view that asthma is a noninfectious condition whose root cause is inflammation. Therefore chronic antiinflammatory therapy, mainly inhaled corticosteroids, is currently advocated as primary anti-asthma treatment. It is important to recognize, however, that antiinflammatory therapy is palliative, not curative.
A growing body of evidence implicates chronic bronchial infection with Chlamydia pneumoniae in the pathogenesis of asthma in both adults and children. Organism identification studies (culture and PCR) suggest that up to one-half of children with asthma may be chronically infected by C. pneumoniae, and seroepidemiologic studies in adults are consistent with chronic C. pneumoniae infection in the majority of adult-onset asthmatics. Furthermore, case reports and uncontrolled trials have provided provocative but inconclusive evidence that treatment of C. pneumoniae infection in both children and adults with asthma can favorably affect the natural history of this disorder.
We propose a randomized, placebo-controlled, triple-blinded study of antichlamydial antimicrobial therapy in adult-onset asthma. Results will help to determine whether antimicrobial therapy is effective in treating some adult asthma syndromes. Positive results would have significant public health implications. Methodologies developed for use in this trial may expedite future studies in practice-based research networks.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | HSC Protocol 98-370-277 |
Study First Received: | October 27, 2005 |
Last Updated: | October 27, 2005 |
ClinicalTrials.gov Identifier: | NCT00245908 |
Health Authority: | United States: Institutional Review Board |
Asthma Chlamydia pneumoniae Chlamydophila pneumoniae Azithromycin |
Hypersensitivity Lung Diseases, Obstructive Respiratory Tract Diseases Azithromycin Lung Diseases |
Chlamydia Infections Hypersensitivity, Immediate Asthma Pneumonia Respiratory Hypersensitivity |
Anti-Infective Agents Anti-Bacterial Agents Immune System Diseases |
Bronchial Diseases Therapeutic Uses Pharmacologic Actions |